CSL pays $117 million for exclusive option to acquire VarmX VarmX could receive up to $388 million if milestones are met CSL funds VarmX's Phase 3 trial for VMX-C001 Sept 16 (Reuters) - Australia's ...
SYDNEY--Australian pharmaceutical company CSL said on Tuesday that it has agreed to a deal to advance a blood coagulation treatment and potentially acquire its closely held Dutch developer. CSL said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback